The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages S109-S116

  Dell'Osso, Lilliana ^a   Bazzichi, Laura ^a   Baroni, Stefano ^a   Falaschi, Valentina ^a   Conversano, Ciro ^a   Carmassi, Claudia ^a   Marazziti, Donatella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bipolar disorders; Chronic fatigue syndrome; Cytokines; Depression; Fibromyalgia; Inflammation; Mood spectrum; Neuroinflammation; Neurotransmitters

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PROSTAGLANDIN E2; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

BRAIN REGION; CENTRAL NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; FIBROMYALGIA; HUMAN; ILLNESS BEHAVIOR; IMMUNE SYSTEM; INFLAMMATION; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; AFFECT; ANIMAL; IMMUNOLOGY; METABOLISM; PSYCHOLOGY;

AFFECT; ANIMALS; CYTOKINES; FATIGUE SYNDROME, CHRONIC; FIBROMYALGIA; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION;

EID: 84929283654     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. KIRSCH I: Antidepressant drugs 'work', but they are not clinically effective. Br J Hosp Med 2008; 69: 359.
2. FELGER JC, LOTRICH FE: Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013; 246: 199-229.
3. McNAMARA RK, LOTRICH FE: Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother 2012; 12: 1143-61.
4. RAJU TN: The nobel chronicles. 1927: Julius Wagner-Jauregg (1857-1940). Lancet 1998; 352: 1714.
5. LOPEZ-MUNOZ F, ALAMO C: Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15: 1563-86.
6. MAES M: The cytokine hypothesis of depression: inflammation, oxidative&nitrosative stress (IO6NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008; 29: 287-91.
7. MAES M, YIRMYIA R, NORABERG J et al.: The inflammatory&neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24: 27-53.
8. ABBAS AK, LICHTMAN AH, PILLAI S: Cellular andmolecular immunology. 7th ed. Philadelphia, PA: Elsevier Saunders 2012.
9. MILLER AH, MALETIC V, RAISON CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-41.
10. ZORILLA EP, LUBOESKY L, McKAY JR, ROESNTHAL R, HOULDIN A, TAX A: The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun 2001; 15: 199-226.
11. RAISON CL, CAPURON L, MILLER AH: Cytokines sing the blues: Inflammation and the pathogenesis of major depression. Trend Immunol 2006; 27: 24-31.
12. MAES M, SCHARPE S, MELTZER HY, COSYNS P: Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol Psychiatry 1993; 34: 690-701.
13. MAES M, VANDOOLAEGHE E, NEELS H et al.: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997; 42: 349-58.
14. QININ L, WU X, BLOCK ML: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55: 453-62.
15. POLAZZI E, CONTESTABILE A: Reciprocal interactions between microglia and neurons: from survival to neuropathology. Rev Neurosci 2002; 13: 221-42.
16. WYSS-CORAY T, MUCKE L: Inflammation in neurodegenerative disease: A double-edged sword. Neuron 2002; 35: 419-32.
17. SIMEN BB, DUMAN CH, SIMEN AA, DUMAN RS: TNFalpha signaling in depression and anxiety: Behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59: 775-85.
18. DANTZER R, O'CONNOR JC, FREUND GG, JOHNSON RW, KELLEY KW: From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
19. DANNER M, KASL SV, ABRAMSON JL, VACCARINO V: Association between depression and elevated C-reactive protein. Psychosom Med 2003; 65: 347-56.
20. DOWLATI Y, HERMANN N, SWARDFAGER W et al.: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-57.
21. FORD DE, ERLINGER TP: Depression and Creactive protein in US adults: data from the third national health and nutrition examination survey. Arch Intern Med 2004; 164: 1010-4.
22. KLING MA, ALESCI S, CSAKO G et al.: Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 2007; 62: 309-13.
23. KOP WJ, GOTTDIENER JS, TANGEN CM et al.: Inflammation and coagulation factors in persons N 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002; 89: 419-24.
24. BOUFIDOU F, NIKOLAOU C, ALEVIZOS B, LIAPPAS IA, CHRISTODOULOU GN: Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord 2004; 82: 309-13.
25. BREUNIS MN, KUPKA RW, NOLEN WA et al.: High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157-65.
26. BRIETZKE E, STERTZ L, FERNANDES BS et al.: Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-7.
27. BERK M, KAPCZINSKI F, ANDREAZZA AC et al.: Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Behav Rev 2011; 35: 804-17.
28. DICKERSON F, STALLING C, ORIGONI A, BORONOW J, YOLKEN RH: Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 952-5.
29. ANISMAN H, POULTER MO, GANDHI R, MERALI Z, HAYLEY S: Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J Neuroimmunol 2007; 186: 45-53.
30. REICHENBERG A, YIRMIYA R, SCHULD A, KRAUS T, HAACK M, MORAG A: Cytokineassociated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-52.
31. BRYDON L, HARRISON N.A, WALKER C, STEPTOE A, CRITCHLEY HD: Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008; 63: 1022-9.
32. HARRISON NA, BRYDON L, WALKER C, GRAY MA, STEPTOE A, CRITCHLEY HD: Inflammation causes mood changes through alterations in subgenual cingulated activity and mesolimbic connectivity. Biol Psychiatry 2009; 66: 407-14.
33. MAES M, MIHAYLOVA I, LEUNIS JC: Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 2007; 99: 237-40.
34. MAES M, KUBERA M, LEUNIS JC: The gutbrain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008; 29: 117-24.
35. BONACCORSO S, PUZELLA A, MARINO V et al.: Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45-55.
36. BONACCORSO S, MARINO V, BIONDI M, GRIMALDI F, IPPOLITI F, MAES M: Depression induced by treatment with interferonalpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-41.
37. BONACCORSO S, MARINO V, PUZELLA A et al.: Increased depressive ratings in patients with hepatitis C receiving interferonalphabased immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
38. MUSSELMAN DL, LAWSON DH, GUMNICK JF, MANATUNGA AK, PENNA S, GOODKIN RS: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-6.
39. CAPURON L, GUMNICK JF, MUSSELMAN DL, LQWSON DH, REEMSNYDER A, NEMEROFF CB: Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacol 2002; 26: 643-52.
40. BRYDON L, WALKER C, WAWRZYNIAK A et al.: Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun 2009; 23: 217-24.
41. WALKER JR, GRAFF LA, DUTZ JP, BERNSTEIN CN: Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J Rheumatol 2011; 88 (Suppl.): 31-5.
42. MAES M, VERKEK R, BONACCORSO S, OMBELET W, BOSMANS E, SCHARPE S: Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002; 71: 1837-48.
43. MENDLEWICZ J, KRIWIN P, OSWALD P, SOUERY D, ALBONI S, BRUNELLO N: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. Int Clin Psychopharmacol 2006; 21: 227-31.
44. MULLER N, SCHWARZ MJ, DEHNING S et al.: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-4.
45. TYRING S, GOTTLIEB A, PAPP K, GORDON K, LEONARDI C, WANG A: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
46. JAZAYERI S, TEHRANI-DOOST M, KESHAVARZ SA et al.: Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42: 192-8.
47. MAES M, SONG C, LIN A et al.: In: Cytokines, Stress and Immunity, Plotnikoff, Faith, Murgo, Good (Eds.) Raven press: Bocaraton 1998: 39-50.
48. MAES M, CHRISTOPHE A, BOSMANS E, LIN A, NEELS H: In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol Psychiatr 2000; 47: 910-20.
49. KENIS G, MAES M: Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002; 5: 401-12.
50. HANNESTAD J, DELLAGIOIA N, BLOCH M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsycho-pharmacology 2011; 36: 2452-9. 2002; 5: 401-12.
51. MARAZZITI D, Dell'OSSO L, GEMIGNANI A et al.: Citalopram in refractory obsessivecompulsive disorder: an open study. Int Clin Psychopharmacol 2001; 16: 215-9.
52. CAPURON L, NEURAUTER G, MUSSELMAN DL et al.: Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906-14.
53. BABCOCK TA, CARLIN JM: Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000; 12: 588-94.
54. MAES M, MIHAYLOVA I, RUYTER MD, KUBERA M, BOSMANS E: The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): Relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007; 28: 826-31.
55. RIOS C, SANTAMARIA A: Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991; 16: 1139-43.
56. SCHWARCZ R, PELLICCIARI R: Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002; 303: 1-10.
57. MULLER N, SCHWARZ MJ: The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000.
58. McNALLY L, BHAGWAGAR Z, HANNESTAD J: Inflammation, glutamate, and glia in depression: A literature review. CNS Spectr 2008; 13: 501-10.
59. WANG J, DUNN AJ: Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 1998; 33: 143-54.
60. ZHANG J, TERRENI L, DE SIMONI MG, DUNN AJ: Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 2001; 38: 303-8.
61. MAES M, RINGEL K, KUBERA M, BERK M, RYBAKOWSKI J: Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012; 136: 386-92.
62. MAES M.; BOSMANS E, MELTZER HY, SCHARPE S, SUY E: Interleukin-1 beta: A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-93.
63. BESEDOVSKY HO, DEL REY A: Immuneneuro-endocrine interactions: Facts and hypotheses. Endocr Rev 1996; 17: 64-102.
64. BEISHUIZEN A, THIJS LG: Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003; 9: 3-24.
65. SILVERMAN MN, MILLER AH, BIRON CA, PEARCE BD: Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology 2004; 145: 3580-9.
66. PACE TW, HU F, MILLER AH: Cytokineeffects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007; 21: 9-19.
67. HOES MJ, SIJBEN N: The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. Psychopharmacology (Berl) 1981.
68. MAES M, LEONARD BE, MYINT AM, KUBERA M, VERKERK R: The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 702-21.
69. WOLF H: The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest 1974; 136 (Suppl.): 1-186.
70. ABRAHAM K: Clinical Papers and Essays on Psycho-Analysis. In HILDA&ABRAHAM Eds; Hogarth Press, London 1955: 336.
71. BIERHAUS A, WOL J, ADRASSY M, ROHLEDER N, HUMPERT PM, PETROV D: A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-5.
72. McDADE TW, HAWKLEY LC, CACIOPPO JT: Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: The Chicago health, aging, and social relations study. Psychosom Med 2006; 68: 376-81.
73. KIECOLT-GLASER JK, LOVING TJ, STOWELL JR, MALARKEY WB, LEMESHOW S, DICKINSON SL: Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry 2005; 62: 1377-84.
74. MILLER GE, CHEN E, SZE J, MARIN T, AREVALO JM, DOLL R: A functional genomic fingerprint of chronic stress in humans: Blunted glucocorticoid and increased NFkappaB signaling. Biol Psychiatry 2008; 64: 266-72.
75. MAES M, SONG C, LIN A et al.: The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stressinduced anxiety. Cytokine 1998; 10: 313-8.
76. CAMPBELL S, MacQUEEN G: An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry 2006; 19: 25-33.
77. McCAFFERY JM, FRASURE-SMITH N, DUBE MP: Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006; 68: 187-200.
78. RUTTEN BP, MILL J: Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull 2009; 35(6): 1045-56.
79. SHAH PJ, EBMEIER KP, GLABUS MF, GOODWIN GM: Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998; 172: 527-32.
80. SHELINE YI, WANG PW, GADO MH, CSERNANSKY JG, VANNIER MW: Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996; 30: 93 3908-13.
81. SHELINE YI, GADO MH, PRICE JL: Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 22: 9 2023-8.
82. SHELINE YI, SANGHAVI M, MINTUN MA, GADO MH: Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 15: 19 5034-43.
83. MacQUEEN GM, CAMPBELL S, MCEWEN BS et al.: Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sc USA 2003; 4: 100 1387-92.
84. SAPOLSKY RM: Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 2004; 56: 137-9.
85. GOSHEN I, KREISEL T, BEN-MENACHEMZIDON O: Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13: 717-28.
86. BERNARDINO L, AGASSE F, SILVA B, FERREIRA R, GRADE S, MALVA JO: Tumor necrosis factor-alpha modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures. Stem Cells 2008; 26: 2361-71.
87. WU CW, CHEN YC, YU L, CHEN HI, JEN CJ, HUANG AM: Treadmill exercise counteracts the suppressive effects of peripheral lipopolysaccharide on hippocampal neurogenesis and learning and memory. J Neurochem 2007; 103: 2471-81.
88. LEONARD BE: The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010; 3: 205-12.
89. KOO, JW, DUMAN RS: IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008; 105: 751-6.
90. RAJKOWSKA G: Postmortem studies in mood disorders indicate altered numbers of neurons and glia cells. Biol Psychiatry 2000; 48: 766-77.
91. HASHIMOTO K, SHIMIZU E, IYO M: Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research Rev 2004; 45: 104-14.
92. LEVINSON DF: The genetics of depression: a review. Biol Psychiatry 2006; 60: 84-92.
93. DUMAN RS, MONTEGGIA LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-27.
94. BELTZ BS, TLUSTY MF, BENTON JL, SANDEMAN DC: Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett 2007; 145: 154-8.
95. HALLIWELL B: Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97: 1634-58.
96. BAZAN NG, MARCHESELLI VL, COLEEDWARDS K: Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann NY Acad Sci 2005; 1053: 137-47.
97. MANCUSO M, COPPEDE F, MIGLIORE L, SICILIANO G, MURRI L: Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimer's Dis 2006; 10: 59-73.
98. POTASHKIN JA, MEREDITH GE: The role of oxidative stress in the dysregulation of gene expression and protein metabolism in neurodegenerative disease. Antioxidant Redox Sign 2006; 8: 144-51.
99. MAES M, MIHAYLOVA I, ATEGIS JC: Evidence for an IgM-mediated immune response directed against nitro-bovine serum albumin (BSA) in chronic fatigue syndrome (CFS) and major depression (MDD): evidence that the immune response to nitrosative stress-induced damage of BSA is more pronounced in CFS than in MDD. Neuro Endocrinol Lett 2008; 29: 313-9.
100. MAES M, CAPURON L, RAVAUD A et al.: Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacol 2001; 24: 130-40.
101. BORLAND LM, MICHAEL AC: Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem 2004; 91: 220-9.
102. ZOU JY, CREWS FT: TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005; 1034: 11-24.
103. VIVIANI B, GARDONI F, BARTESAGHI S et al.: Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J Biol Chem 2006; 281: 30212-32.
104. PATEL HC, ROSS FM, HEENAN, DAVIES RE, ROTHWELL NJ, ALLAN SM: Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. J Neurosci Res 2006; 83: 385-91.
105. WHITE KP, HARTH M: Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001; 5: 320-9.
106. NEUMANN L, BUSKILA D: Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003; 7: 362-8.
107. WOLFE F, SMYTHE HA, YUNUS MB et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160-72.
108. CLAW DJ, CROFFORD LJ: Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 685-701.
109. MEASE PJ: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005; 75: 6-21.
110. GIACOMELLI C, SERNISSI F, SARZI-PUTTINI P, DI FRANCO M, ATZENI F, BAZZICHI L: Fibromyalgia: a critical digest of the recent literature. Clin Exp Rheumatol 2013; 31(Suppl. 79): S153-7.
111. ARNOLD LM, HUDSON JI, KECK PE JR, AUCHENBACH MB, JAVARAS KN, HESS EV: Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006; 67: 1219-25.
112. WOLFE F, ROSS K, ANDERSON J, RUSSELL IJ, HEBERT L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
113. HOFFMAN DL, DUKES EM: The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008; 62: 115-26.
114. WHITE LA, BIRNBAUM HG, KALTENBOECK A, TANG J, MALLETT D, ROBINSON RL: Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008; 50: 13-24.
115. POLLACK S: Mast cells in fibromyalgia. Clin Exp Rheumatol 2015; 33 (Suppl. 88): S140.
116. PRADOS G, MIRÓ E, MARTÍNEZ MP, SÁNCHEZ AI, LÓPEZ S, SÁEZ G: Fibromyalgia: gender differences and sleep-disordered breathing. Clin Exp Rheumatol 2013; 31(Suppl. 79): S102-10.
117. BENNETT R: Fibromyalgia: present to future. Curr Rheumatol Rep 2005; 7: 371-6.
118. GRACELY RH, PETZKE F, WOLF JM, CLAW DJ: Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46: 1333-43.
119. WOOLF CJ: Moving from symptom control toward mechanismspecific pharmacologic management. Ann Intern Med 2004; 140: 441-51.
120. STAUD R, RODRIGUEZ ME: Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract 2006; 2: 90-8.
121. LA RUBIA M, RUS A, MOLINA F, DEL MORAL ML: Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status? Clin Exp Rheumatol 2013; 31 (Suppl. 79): S121-7.
122. FATIMA G, DAS SK, MAHDI AA: Oxidative stress and antioxidative parameters and metal ion content in patients with fibromyalgia syndrome: implications in the pathogenesis of the disease. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S128-33.
123. CLAW DJ: Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 2008; 69 (Suppl. 2): 25-9.
124. HUYNH CN, YANNI LM, MORGAN LA: Fibromyalgia: diagnosis and management for the primary healthcare provider. J Womens Health (Larchmt) 2008; 17: 1379-87.
125. STAHL SM, GRADY MM, MORET C, BRILEY M: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10: 732-47.
126. BRILEY M, MORET C: Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr 2008; 13(Suppl. 11): 22-6.
127. BAZZICHI L, DA VALLE Y, ROSSI A et al.: A multidisciplinary approach to study the effects of balneotherapy and mud-bath therapy treatments on fibromyalgia. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S111-20.
128. DANTZER R: Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004; 500: 399-411.
129. KENT S, BLUTHE RM, KELLEY KW, DANTZER R: Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13: 24-8.
130. GUR A, KARAKOC M, NAS K, CEVIK R, DENLI A, SARAC J: Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002; 29: 358-61.
131. WALLACE DJ, LINKER-ISRAELI M, HALLEGUA D, SILVERMAN S, SILVER D, WEISMAN MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001; 40: 743-9.
132. ZHANG Z, CHERRYHOLMES G, MAO A et al: High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med (Maywood) 2008a; 233: 1171-80.
133. BAZZICHI L, ROSSI A, GIACOMELLI C et al.: The influence of psychiatric comorbidity on sexual satisfaction in fibromyalgia patients. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S81-5.
134. YENER M, ASKIN A, SOYUPEK F et al.: The evaluation of anxiety and depression status in spouses of sexually active reproductive women with fibromyalgia. Clin Exp Rheumatol 2015; 33 (Suppl. 88): S20-24.
135. PERNAMBUCO AP, SCHETINO LP, VIANA RS, CARVALHO LS, D'ÁVILA REIS D: The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 2015; 33 (Suppl. 88): S14-19.
136. CAPURON L, DANTZER R: Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17: S119-24.
137. PENNINX BW, KRITCHEVSKY SB, YAFFE K et al.: Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 2003; 54: 566-72.
138. MIKOVA O, YAKIMOVA R, BOSMANS E,KENIS G, MAES M: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001; 11: 203-8.29.
139. HAACK M, HINZE-SELCH D, FENZEL T et al.: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-18.
140. BAZZICHI A, ROSSI G, MASSIMETTI G et al.: Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007; 25: 225-30.
141. FENG J, ZHANG Z, LI W et al.: Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. PLoS ONE 2009; 4: e8480.
142. SALEMI S, RETHAGE J, WOLLINA U et al.: Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003; 30: 146-50.
143. WANG LK, LABAR S, SMOSKI M et al.: Prefrontal mechanisms for executive control over emotional distraction are altered in major depression. Psychiatry Res 2008; 163: 143-55.
144. BOWLEY MP, DREVETS WC, ONGUR D, PRICE JL: Low glial numbers in the amygdale in major depressive disorder. Biol Psychiatry 2002; 52: 404-12.
145. MARAZZITI D, CONSOLI G, MASALA I, CATENA DELL'OSSO M, BARONI S: Latest advancements on serotonin and dopamine transporters in lymphocytes. Mini Rev Med Chem 2010; 10: 32-40.
146. MARAZZITI D, BARONI S, CATENA Dell'OSSO et al.: Presence and characterization of the dopamine transporter in human resting lymphocytes. Neurochem Res 2008 Jun; 33: 1011-6.
147. MARAZZITI D, ROSSI A, GIANNACCINI G, BARONI S, LUCACCHINI A, CASSANO GB: Presence and characterization of the serotonin transporter in human resting lymphocytes. Neuropsychopharmacology 12: 154-9.
148. MARAZZITI D, LANDI P, BARONI S et al.: The role of platelet/lymphocyte serotonin transporter in depression and beyond. Curr Drug Targets 2013; 14: 522.
149. MARAZZITI D, AMBROGI F, VANACORE R et al.: Immune cell imbalance in major depressive and panic disorders. Neuropsychobiology 1992; 26: 23-6.